Unknown

Dataset Information

0

Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.


ABSTRACT: Patients with lower-risk myelodysplastic syndromes (LR-MDS) as defined by the International Prognostic Scoring System (IPSS) have more favorable prognosis in general, but significant inter-individual heterogeneity exists. In this study, we examined the molecular profile of 15 MDS-relevant genes in 159 patients with LR-MDS using next-generation sequencing. In univariate COX regression, shorter overall survival (OS) was associated with mutation status of ASXL1 (P = .001), RUNX1 (P = .031), EZH2 (P = .049), TP53 (P = .016), SRSF2 (P = .046), JAK2 (P = .040), and IDH2 (P = .035). We also found significantly shorter OS in patients with an adjusted TET2 variant allele frequency (VAF) ?18% versus those with either an adjusted TET2 VAF <18% or without TET2 mutations (median: 20.4 vs 47.8 months; P = .020; HR = 2.183, 95%CI: 1.129-4.224). After adjustment for IPSS, shorter OS was associated with mutation status of ASXL1 (P < .001; HR = 4.306, 95% CI: 2.144-8.650), TP53 (P = .004; HR = 4.863, 95% CI: 1.662-14.230) and JAK2 (P = .002; HR = 5.466, 95%CI: 1.848-16.169), as well as adjusted TET2 VAF ?18% (P = .008; HR = 2.492, 95% CI: 1.273-4.876). Also, OS was increasingly shorter as the number of mutational factors increased (P < .001). A novel prognostic scoring system incorporating the presence/absence of the four independent mutational factors into the IPSS further stratified LR-MDS patients into three prognostically different groups (P < .001). The newly developed scoring system redefined 10.1% (16/159) of patients as a higher-risk group, who could not be predicted by the currently prognostic models. In conclusion, integration of the IPSS with mutation status/burden of certain MDS-relevant genes may improve the prognostication of patients with LR-MDS and could help identify those with worse-than-expected prognosis for more aggressive treatment.

SUBMITTER: Jiang L 

PROVIDER: S-EPMC7004535 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.

Jiang Lingxu L   Luo Yingwan Y   Zhu Shuanghong S   Wang Lu L   Ma Liya L   Zhang Hua H   Shen Chuying C   Yang Wenli W   Ren Yanling Y   Zhou Xinping X   Mei Chen C   Ye Li L   Xu Weilai W   Yang Haiyang H   Lu Chenxi C   Jin Jie J   Tong Hongyan H  

Cancer science 20191224 2


Patients with lower-risk myelodysplastic syndromes (LR-MDS) as defined by the International Prognostic Scoring System (IPSS) have more favorable prognosis in general, but significant inter-individual heterogeneity exists. In this study, we examined the molecular profile of 15 MDS-relevant genes in 159 patients with LR-MDS using next-generation sequencing. In univariate COX regression, shorter overall survival (OS) was associated with mutation status of ASXL1 (P = .001), RUNX1 (P = .031), EZH2 (P  ...[more]

Similar Datasets

| S-EPMC6848148 | biostudies-literature
| S-EPMC6113605 | biostudies-literature
| S-EPMC6609480 | biostudies-literature
| S-EPMC6913460 | biostudies-literature
| S-EPMC9751093 | biostudies-literature
| S-EPMC9713208 | biostudies-literature
| S-EPMC3438234 | biostudies-literature
| S-EPMC4751065 | biostudies-literature
| S-EPMC7000478 | biostudies-literature
| S-EPMC7812395 | biostudies-literature